Giuseppe Oliva, Tecnoss®’s FounderUnlike anorganic xenografts, where ceramisation removes the biological matrix and limits regenerative potential, OsteoBiol® by Tecnoss® preserves the native collagen structure within bone granules, enabling active participation in the healing process. This results in a structure composed of hydroxyapatite and ~22 percent collagen that is chemically and physically similar to autogenous bone. By retaining collagen, the biomaterial preserves biological signalling, enabling vascularisation, cellular recruitment and progressive resorption that supports both bone and soft tissue regeneration.
The OsteoBiol® product line is designed for several surgical applications, reducing procedural complexity while limiting invasiveness. Within the portfolio, OsteoBiol® mp3® serves as a graft material that undergoes gradual resorption and is replaced by newly formed bone. OsteoBiol® GTO®, a ready-to-use sticky bone, is changing the way oral surgeons approach horizontal defects, while OsteoBiol® Lamina® can be used to reconstruct missing bony walls.
“Our biomaterials are designed to benefit patients through improved surgical handling, reduced operative times and minimised procedural invasiveness,” says Giuseppe Oliva, Tecnoss®’s founder.
Collagen-Driven Biological Activity
Collagen plays a central role in early bone healing and vascularisation. Its preservation within OsteoBiol® biomaterials supports endothelial cell proliferation and new blood vessel formation, enabling oxygen and nutrient delivery and, in turn, sustaining osteogenic activity.
In vitro studies on human umbilical vein cells demonstrate a more extensive capillary-like network formation with OsteoBiol® bone substitutes compared to non-collagenic xenografts. The preserved matrix facilitates the recruitment of osteoclasts and osteoblasts and supports the differentiation of stem cells into osteogenic cells. This coordinated activity drives a controlled biological turnover in which the graft is gradually resorbed and replaced by vital bone that integrates with the titanium implant surface over time.
Because ceramisation is avoided, the biological matrix remains active, allowing the graft to participate directly in regeneration rather than acting as a passive scaffold. Adequate vascularisation further supports long-term functional integration, while the material’s handling properties enable precise adaptation and stability at the defect site.
Clinically, this translates, for example, into minimally invasive reconstruction of compromised extraction sockets, including in the esthetic zone, without the need for autogenous bone chips. When combined with OsteoBiol® Lamina®, clinicians have extended the boundaries of immediate implant procedures.
-
Our biomaterials are designed to benefit patients through improved surgical handling, reduced operative times and minimised procedural invasiveness.
Clinically, this translates, for example, into minimally invasive reconstruction of compromised extraction sockets, including in the esthetic zone, without the need for autogenous bone chips. When combined with OsteoBiol® Lamina®, clinicians have extended the boundaries of immediate implant procedures.
Regenerative Outcomes Backed by Clinical Research
Tecnoss® anchors its OsteoBiol® Dual-Phase bone substitutes in long-term experimental and clinical histomorphometric evidence that consistently demonstrates abundant newly formed bone with minimal residual biomaterial at the time of implant placement. In one early rabbit model, more than 40 percent of the newly formed bone and less than 10 percent of the biomaterial were observed two months after surgery, demonstrating the rapid turnover associated with collagen-preserved grafts.
This biological profile has direct clinical implications. As the graft is progressively resorbed and replaced by vital bone, clinicians can re-enter within four to five months with adequate implant stability.
Histological and clinical evidence support these outcomes across multiple indications, including socket preservation, ridge augmentation and sinus floor elevation. Studies on transcrestal sinus floor elevation using OsteoBiol® Putty report complete biomaterial resorption and up to 49.2% newly formed bone. Comparative long-term evaluations of OsteoBiol® mp3® against autogenous bone chips over three years show comparable histological and clinical outcomes.
Beyond bone regeneration, OsteoBiol® GTO® has demonstrated the ability to stimulate gingival cell proliferation in vitro, indicating a potential benefit in soft tissue healing.
OsteoBiol®’s properties are supported by more than 350 scientific publications and consistently validated in clinical practice by hundreds of thousands of dentists worldwide. Its consistent selection reflects a combination of surgical handling efficiency, predictable regenerative performance and long-term implant stability.
In recognition of this sustained clinical and scientific contribution, Tecnoss® has been named Top Xenogenic Biomaterials Designs and Manufacturer in Europe 2026 by Life Sciences Review Europe.
Advancing Bone Regeneration Through Collagen-Preserved Xenogenic Biomaterials
Executives responsible for selecting biomaterials for bone regeneration face a persistent tension between biological performance and procedural efficiency. Conventional xenografts, often processed at high temperatures, remove organic components to achieve structural stability, yet this approach significantly influences the material’s interaction with living tissue. The result is a slower integration process, limited vascular response and residual graft material that does not fully resorb. In clinical settings where predictability, healing timelines and implant stability must align, such compromises can introduce variability in outcomes.
A more refined approach has emerged through biomaterials that retain biological elements, particularly collagen. Preservation of collagen within the graft matrix changes how the material participates in early healing. It supports the formation of microvascular networks, allowing oxygen and nutrients to reach regenerating tissue more effectively. This shift influences not only the speed of recovery but also the quality of the regenerated bone. Surgeons evaluating options increasingly look beyond structural compatibility and consider how materials actively contribute to biological processes during the initial weeks following implantation.
The interplay between resorption and regeneration further shapes long-term results. Materials that cannot be gradually resorbed by osteoclasts reduce the amount of newly formed bone, while those that resorb too quickly may compromise structural support. A balanced, progressive resorption profile allows the graft to be replaced by newly formed bone at a pace that maintains stability while encouraging integration. Clinical evidence has shown that when this balance is achieved, re-entry timelines can shorten without sacrificing implant anchorage, creating efficiencies that extend beyond the operating room into overall treatment planning.
Handling characteristics also carry weight in decision-making. Materials that adapt easily to defect sites reduce surgical complexity and improve placement accuracy. This directly influences operative time and the consistency of outcomes across different indications such as socket preservation, ridge augmentation and sinus elevation. Ease of use becomes a practical advantage, especially in high-volume practices where procedural reliability must be maintained across varying clinical scenarios. Consistency across cases also supports protocol standardisation, which is increasingly important for organisations managing multi-site clinical operations and striving to reduce variability in outcomes.
Another emerging consideration is the ability of biomaterials to support both hard and soft tissue healing in parallel. Early-stage gingival response, alongside bone regeneration, can influence aesthetic outcomes and long-term implant success. Materials that contribute to cellular proliferation in surrounding tissues offer an added layer of predictability, particularly in procedures performed in visible anatomical regions where patient expectations are high.
Tecnoss® presents a differentiated model through its OsteoBiol® portfolio, which integrates collagen preservation into the design of xenogenic biomaterials. Its DualPhase structure combines hydroxyapatite with a collagen component that mirrors the composition of natural bone, supporting vascularisation and cellular activity during early healing. Clinical studies have demonstrated that this approach leads to substantial new bone formation with minimal residual material, enabling clinicians to proceed with implant placement within defined timeframes while maintaining stability. The portfolio spans multiple formulations, including injectable bone granules and cortical collagenic bone lamina, enabling tailored application across surgical indications. By supporting biological integration while simplifying handling and reducing procedural invasiveness, it offers a coherent solution for organisations that prioritise both clinical performance and treatment efficiency.
...Read more
Xenogenic Biomaterial Design and Manufacturing Companies in Europe Info
Q1
What Should Clinicians Expect from Xenogenic Biomaterials Design and Manufacturing Companies in Europe?
Xenogenic Biomaterials Design and Manufacturing Companies in Europe should give clinicians more than volume replacement. In oral and implant surgery, the material has to support handling at the defect site, biological integration, gradual resorption and a realistic healing timeline. Collagen-preserved grafts are valued because they can participate in vascularisation and cellular activity rather than behaving only as inert filler. A poor material fit can leave the surgeon managing stability, re-entry timing and patient expectations later.
Q2
How Does Tecnoss Approach Xenogenic Biomaterial Design?
Tecnoss connects Xenogenic Biomaterials Design and Manufacturing Companies in Europe with a collagen-preservation model built around OsteoBiol. Its Dual-Phase bone substitutes retain native collagen within bone granules, creating a hydroxyapatite-and-collagen structure close to autogenous bone composition. The company’s portfolio includes mp3 for gradual replacement by new bone, GTO ready-to-use sticky bone for horizontal defects and Lamina for structural support and graft volume maintenance. These formats give surgeons different ways to match the material to the defect rather than forcing one graft style across every case.
Q3
Why Does Collagen Preservation Matter in Dental Regeneration?
Collagen preservation matters because early healing depends on blood vessel formation, cell recruitment and the pace at which the graft gives way to vital bone. Xenogenic Biomaterials Design and Manufacturing Companies in Europe that avoid stripping away the biological matrix can help clinicians balance scaffold stability with regeneration. For patients, that balance can mean less invasive reconstruction, fewer donor-site concerns and clearer planning for implant placement. It also keeps the discussion focused on healing quality, not only the amount of material placed.
Q4
Which Quality Signals Matter When Evaluating These Biomaterials?
Buyers should look beyond product descriptions and review the evidence behind processing, sterility, handling, resorption and clinical follow-up. Strong Xenogenic Biomaterials Design and Manufacturing Companies in Europe can show how a material behaves in socket preservation, ridge augmentation and sinus floor elevation, not just in a laboratory note. A useful review asks what remains at re-entry, how the graft adapts during placement and whether the evidence matches daily surgical use. That evidence should also be easy for clinical teams to interpret.
Q5
How Do These Materials Improve Surgical Handling?
Surgery often turns on small details: how a graft packs, whether it stays where it is placed and how well it suits the defect shape. Xenogenic Biomaterials Design and Manufacturing Companies in Europe address that friction through forms such as granules, putties, sticky bone and collagenic laminae. Good handling can reduce chair time, limit unnecessary manipulation and make the reconstruction easier to repeat across different clinical indications. For busy implant practices, repeatability is part of clinical quality.
Q6
What Makes Tecnoss Relevant for Long-Term Regenerative Planning?
Tecnoss adds manufacturing depth to Xenogenic Biomaterials Design and Manufacturing Companies in Europe through a history dating to 1998, a patented tissue-conditioning and deantigenation process and production based in Giaveno, Turin. OsteoBiol products are supported by more than 350 scientific publications and use by large numbers of dentists worldwide. That background matters when clinicians need repeatable graft behaviour, documented healing patterns and materials that fit established implant workflows.
